scholarly journals Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: a review

2021 ◽  
Vol 6 (1) ◽  
pp. e000663
Author(s):  
Samra Rahman ◽  
Muhammad Irfan ◽  
M A Rehman Siddiqui
Keyword(s):  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Limited Evidence ◽  
Ocular Tuberculosis ◽  
Diagnosis And Management ◽  
Pubmed Database ◽  
Interferon Gamma Release Assays ◽  
Infectious Uveitis ◽  
Release Assay

Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: ‘interferon-gamma release assay’, ‘QuantiFERON’, ‘T-SPOT.TB’, ‘TB uveitis’, ‘serpiginous like choroiditis’, ‘tuberculoma’, ‘TB vasculitis’, ‘TB panuveitis’ and ‘ocular tuberculosis’. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test—the QFT-Plus—in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.

scholarly journals Short-Term Reproducibility of a Commercial Interferon Gamma Release Assay

2009 ◽  
Vol 16 (8) ◽  
pp. 1170-1175 ◽  
Author(s):  
A. K. Detjen ◽  
L. Loebenberg ◽  
H. M. S. Grewal ◽  
K. Stanley ◽  
A. Gutschmidt ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Health Care Workers ◽  
Immune Memory ◽  
Interferon Gamma Release Assay ◽  
Short Term ◽  
Care Workers ◽  
Interferon Gamma Release Assays ◽  
Release Assay ◽  
Ifn Γ ◽  
Storage Methods

ABSTRACT Interferon gamma release assays (IGRAs) have been shown to be sensitive and highly specific for the detection of immune memory against Mycobacterium tuberculosis. Little is known about the reproducibility and within-person variability of these assays. Various aspects of short-term reproducibility of a commercial IGRA, the QuantiFERON-TB Gold In-Tube (QFT-IT) assay, were assessed. The QFT-IT assay was performed twice within 3 days in 27 health care workers in Cape Town, South Africa. Two sets of tests were performed by different operators on day 1, and one set was performed on day 3. Aspects such as interoperator, intraoperator, day-to-day variability, and test-retest variability as well as different the storage methods of plasma were investigated. Seventeen of 27 (63%) of participants had at least one positive QFT-IT text; six had discordant results. The agreement of all aspects studied was high, with kappa values between 0.82 and 1.00 for dichotomous measures, and interclass correlations (ICC) of 0.809 to 0.965 were observed for continuous gamma interferon (IFN-γ) measures. The variability of the magnitude of response was highest comparing measures obtained from individuals on different days (ICC of 0.809). The magnitude of the IFN-γ responses between assays performed for individual participants was variable, with ranges from 0.03 to 11 IU/ml, resulting is discordant results for five participants. The results indicate that the QFT-IT assay is a robust and highly reproducible assay. Considerable intraindividual variability occurs in the magnitude of IFN-γ responses, which may influence the interpretation of serial measures.

scholarly journals Association of Low Sputum Smear Positivity among Tuberculosis Patients with Interferon-Gamma Release Assay Outcomes of Close Contacts in Japan

2019 ◽  
Vol 16 (19) ◽  
pp. 3713
Author(s):  
Tsuyoshi Ogata ◽  
Natsuki Nagasu ◽  
Ritei Uehara ◽  
Kunihiko Ito
Keyword(s):  
Interferon Gamma ◽  
Acid Fast Bacillus ◽  
Sputum Smear ◽  
Interferon Gamma Release Assay ◽  
Tuberculosis Patients ◽  
Interferon Gamma Release Assays ◽  
Response Measures ◽  
Release Assay ◽  
Smear Negative ◽  
Close Contacts

Risk prediction and response measures may differ in tuberculosis (TB) patients with low sputum smear positivity for acid-fast bacillus (AFB) compared to those who are smear negative. However, previous studies using the tuberculin skin test (TST) did not show that differences in measures are important. This study compared results of interferon-gamma release assays (IGRA) between contacts of pulmonary TB patients with AFB smear positivity and those with smear negativity using QuantiFERON®-TB Gold In-Tube (QFT) assays. Close contacts of TB patients with culture-confirmed infections between April 2010 and December 2012 in Ibaraki, Japan, were enrolled, and 439 Japanese contacts of 129 index TB patients were examined. Adjusted odds ratios of QFT in contacts were 0.68 (95% confidence interval: 0.17–2.8) for AFB scanty patients, 1.12 (0.45–2.8) for AFB 1+, 1.20 (0.48–3.0) for AFB 2+, and 4.96 (1.9–12.9) for AFB 3+, compared to those who were smear negative. Differences in IGRA positivity were not significant between close contacts of TB patients with low positive and negative smears.

scholarly journals Specificity of QuantiFERON-TB Plus, a New-Generation Interferon Gamma Release Assay

2018 ◽  
Vol 56 (12) ◽  
Author(s):  
S. A. R. Siegel ◽  
M. Cavanaugh ◽  
J. H. Ku ◽  
L. M. Kawamura ◽  
K. L. Winthrop
Keyword(s):  
Interferon Gamma ◽  
High Specificity ◽  
The United States ◽  
Interferon Gamma Release Assay ◽  
Content Type ◽  
Interferon Gamma Release Assays ◽  
Release Assay ◽  
Increased Sensitivity ◽  
New Generation ◽  
Age Range

ABSTRACT Interferon gamma release assays (IGRAs) are important tools in identifying prior tuberculosis exposure. The new-generation QuantiFERON-TB Gold Plus (QFT-Plus) assay, recently approved for use in the United States, differs from the current-generation QFT Gold-In-Tube (QFT-GIT) assay with the addition of a second antigen tube that also contains novel CD8+ T-cell-stimulating peptides. The QFT-Plus assay has increased sensitivity in immunocompromised populations, and we sought to assess the specificity of QFT-Plus compared to that of QFT-GIT in low-risk individuals. We enrolled adults without tuberculosis risk factors, including a subgroup with pulmonary nontuberculous mycobacterial (NTM) disease due to Mycobacterium avium complex (MAC) or Mycobacterium abscessus. The primary outcome measures included specificity, interassay concordance, and agreement between the QFT-Plus and QFT-GIT assays. Of 262 participants enrolled, 51 had pulmonary NTM. The median age was 39 years (age range, 18 to 78 years); 73% were female. Among the 262 individuals who were enrolled, 5 (1.9%) individuals had positive QFT-Plus results, and 3 of these individuals also had positive QFT-GIT results. The two individuals with discordant results (QFT-Plus positive/QFT-GIT negative) had only one tube positive in the QFT-Plus assay. The overall specificity of QFT-Plus and QFT-GIT was 98.1% (95% confidence interval [CI], 95.6, 99.4%) and 98.9% (95% CI, 96.7, 99.8%), respectively. The QFT-Plus specificity was similar in both the NTM (98.0% [95% CI, 89.4, 99.9%]) and non-NTM (98.1% [95% CI, 95.2, 99.5%]) groups. QFT-Plus has a high specificity, similar to that of the QFT-GIT assay, including in patients with pulmonary MAC or M. abscessus disease.

scholarly journals Role of Interferon Gamma Release Assay in Active TB Diagnosis among HIV Infected Individuals

PLoS ONE ◽  
2009 ◽  
Vol 4 (5) ◽  
pp. e5718 ◽  
Author(s):  
Basirudeen Syed Ahamed Kabeer ◽  
Rajasekaran Sikhamani ◽  
Sowmya Swaminathan ◽  
Venkatesan Perumal ◽  
Paulkumaran Paramasivam ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Release Assay

scholarly journals Utility of an interferon-gamma release assay as a potential diagnostic aid for active pulmonary tuberculosis

2011 ◽  
Vol 6 (01) ◽  
pp. 67-72 ◽  
Author(s):  
Lynn Taki-Eddin ◽  
Fawza Monem
Keyword(s):  
Real Time ◽  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Pulmonary Tb ◽  
Active Pulmonary Tuberculosis ◽  
Positive Predicted Value ◽  
Release Assay ◽  
Latent Tb ◽  
Sensitivity Specificity

Introduction: Sensitivity, specificity, early confirmation and obtaining an optimal specimen are challenging problems in active tuberculosis (TB) diagnosis. Interferon-gamma release assay (IGRA) is a good indicator for latent TB but can it be useful as a diagnostic tool for active TB? This study was designed to address these challenges and assess the potential of IGRA as a diagnostic indicator of active pulmonary TB by comparing it with other MT diagnostic conventional methods and molecular methods.Methodology: The study was conducted on 91 patients with suspicion of pulmonary active TB. QuantiFERON-TB-Gold In-Tube, a commercial IFN-gamma assay, was compared with Ziehl Neelsen (ZN) smear, Lowenstein Jensen's (LJ) egg-based culture, and real-time polymerase chain reaction. The final clinical diagnosis was the standard comparator of the study.Results: Active pulmonary TB was confirmed in 48/91 (52.7%) patients. Sensitivity, specificity, positive predicted value (PPV), and negative predicted value (NPV) were 72.9%, 100%, 100%, 76.78% for ZN smear, 77.1%, 97.67%, 97.36%, 79.24% for LJ culture, 89.9%, 67.4%, 75.4%, 85.3% for IGRA, and 66.6%, 95.3%, 94.1%, 71.9% for real-time PCR, respectively.  Conclusion: Albeit confounding in the case of latent TB infected patients presenting with non-TB pulmonary disease, IGRA was more sensitive than the other conventional and molecular methods, so it may improve diagnostic accuracy when used in combination with other standard methods. High NPV of IGRA for the diagnosis of active TB proposed an additional role of this test to exclude the infection with active TB.

scholarly journals The Role of Interferon-gamma Release Assay in Tuberculosis Control

2012 ◽  
Vol 63 (1) ◽  
pp. 49-59 ◽  
Author(s):  
Anamarija Jurčev-Savičević ◽  
Vera Katalinić-Janković ◽  
Kornelija Miše ◽  
Ivan Gudelj
Keyword(s):  
Interferon Gamma ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Interferon Gamma Release Assay ◽  
Tuberculosis Control ◽  
Aggressive Approach ◽  
Release Assay ◽  
Low Incidence

The Role of Interferon-gamma Release Assay in Tuberculosis ControlTuberculosis is still one of the major global public health threats. Countries with low incidence must focus on exhausting the reservoir of future cases by preventing reactivation. Therefore, it is important to identify and effectively treat those individuals who have latent tuberculosis infection and who may develop active disease. The tuberculin skin test has been the standard for detection of immune response against M. tuberculosis since the beginning of the 20th century. The new millennium has brought advancement in the diagnosis of latent tuberculosis infection. The name of the new blood test is interferon-gamma release assay (IGRA). Croatia is a middle-incidence country with a long decreasing trend and developed tuberculosis control. To reach low incidence and finally eliminate tuberculosis, its tuberculosis programme needs a more aggressive approach that would include intensive contact investigation and treatment of persons with latent tuberculosis infection. This article discusses the current uses of IGRA and its role in tuberculosis control.

scholarly journals The Role of the Interferon Gamma Release Assay in Assessing Recent Tuberculosis Transmission in a Hospital Incident

PLoS ONE ◽  
2011 ◽  
Vol 6 (6) ◽  
pp. e20770 ◽  
Author(s):  
Louise Bradshaw ◽  
Elizabeth Davies ◽  
Michael Devine ◽  
Peter Flanagan ◽  
Paul Kelly ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Tuberculosis Transmission ◽  
Release Assay
Sign in / Sign up

Export Citation Format

Share Document